Icon (NASDAQ:ICLR – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its rivals? We will compare Icon to similar businesses based on the strength of its earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Profitability
This table compares Icon and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Icon | 5.45% | 7.73% | 4.39% |
| Icon Competitors | -477.84% | 79.93% | -12.81% |
Analyst Ratings
This is a summary of current recommendations for Icon and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Icon | 1 | 9 | 9 | 1 | 2.50 |
| Icon Competitors | 960 | 3201 | 5533 | 179 | 2.50 |
Icon currently has a consensus target price of $213.76, suggesting a potential upside of 12.29%. As a group, “Life Sciences Tools & Services” companies have a potential upside of 1.64%. Given Icon’s stronger consensus rating and higher probable upside, analysts plainly believe Icon is more favorable than its rivals.
Insider & Institutional Ownership
95.6% of Icon shares are held by institutional investors. Comparatively, 53.5% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 44.0% of Icon shares are held by insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Icon has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Icon’s rivals have a beta of 0.94, suggesting that their average stock price is 6% less volatile than the S&P 500.
Valuation and Earnings
This table compares Icon and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Icon | $8.25 billion | $229.34 million | 32.76 |
| Icon Competitors | $2.26 billion | $55.87 billion | -8.01 |
Icon has higher revenue, but lower earnings than its rivals. Icon is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Icon beats its rivals on 10 of the 13 factors compared.
Icon Company Profile
ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
